LAWRENCE, Mass., May 7 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its wholly-owned subsidiary, Medisystems Corporation, has entered into a new supply and distribution agreement with Kawasumi Laboratories, Inc. regarding Kawasumi's continued supply of blood tubing sets to Medisystems through January 31, 2010.
"We are pleased to extend our long-standing relationship with Kawasumi for blood tubing sets," said Jeffrey H. Burbank, President and Chief Executive Officer of NxStage Medical. "I believe NxStage is well positioned to preserve and build upon Medisystems' reputation for high quality and to grow the business further with new and innovative products for our customers. This is another significant agreement that we have successfully renewed since acquiring the company. I am pleased with the progress that we continue to see in this business."
Headquartered in Tokyo, Japan, Kawasumi Laboratories, Inc. has been providing high quality medical supplies worldwide since 1957. Kawasumi has been a pioneer in plastic molding technologies in Japan and has grown its proprietary manufacturing know-how in the markets of medical devices and pharmaceuticals.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at http://www.nxstage.com.
This release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. All statements
contained in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended to
identify forward-looking statements. Examples of these forward-looking
statements include statements as to the anticipated benefits of the
Company's new agreement with Kawasumi, the expected performance of the
Medisystems' business, and the development of new and innovative products.
All forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond NxStage's control, which may cause
actual results, performance, or achievements to differ materially from
anticipated results, performance or achievements. Certain factors which may
affect future operating results are detailed in NxStage's filings with the
Securities and Exchange Commission, including the Annual Report on Form
10-K for the year ended December 31, 2007. In addition, the statements in
this press release represent NxStage's expectations and beliefs as of the
date of this press release. NxStage anticipates that subsequent events and
developments may cause these expectations and beliefs to change. However,
while NxStage may elect to update these forward-looking statements at some
point in the future, it specifically disclaims any obligation to do so,
whether as a result of new information, future events, or otherwise. These
forward-looking statements should not be relied upon as representing
NxStage's expectations or beliefs as of any date subsequent to the date of
this press release.
Investor Relations Contact
Stephanie Marks for NxStage
|SOURCE NxStage Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved